The miR-148/152 family (miR-148a, miR-148b, miR-152) is differentially expressed in
gastric cancer tissues and non-
tumor tissues. Our previous studies indicated that miR-148/152 family is important in the
tumorigenesis and development of
gastric cancer. We also found several target genes that were regulated by the miR-148/152 family and several factors that could influence members of this family. However, the molecular mechanisms and function of this family in
gastric cancer remain unclear. Recently, long non-coding RNAs (lncRNAs) have been found to play an important role in the pathogenesis of many diseases. The aim of the present study was to perform expression profiling to identify lncRNAs that might be associated with miR-148b in
gastric cancer and predict their potential functions. Total
RNA was extracted from
gastric cancer cell line SGC-7901 treated with miR-148b mimics and from untreated
gastric cancer cells. Microarray analysis was performed using the Agilent
LncRNA +
mRNA Human Gene Expression Microarray V3.0 platform, which was designed for the profiling of human lncRNAs and
protein-coding transcripts. A total of 37581
lncRNA and 34303
mRNA transcripts were detected in
gastric cancer cell line SGC-7901 and cell line SGC-7901 treated with miR-148b mimics. Among the differentially expressed lncRNAs, 240 up-regulated and 64 down-regulated lncRNAs were identified. XLOC_000983 was the most up-regulated
lncRNA, and M18204.1 was the most down-regulated
lncRNA. Among the differentially expressed mRNAs in different cell lines, 196 were consistently up-regulated and 320 were consistently down-regulated. POSTN was the most up-regulated
mRNA, and HBB was the most down-regulated
mRNA. Gene Ontology (GO) and pathway analyses indicated that the lncRNAs influenced by miR-148b might play an important role in the immune system and were associated with the development of
gastric cancer. The altered expression of lncRNAs influenced by miR-148b may play a partial role in pathways implicated in
gastric cancer development and progression, such as the immune response pathway.